Troubled GPC cuts staff, looks for M&A deals

The failure of GPC Biotech's cancer drug satraplatin in a Phase III trial is being paid for with the jobs of 44 percent of its workforce. PC announced late last week that it needed to significantly cut back to account for the setback. Now the company says it will concentrate "internal efforts on a limited number of development-stage oncology projects, significantly increasing our licensing efforts and actively exploring M&A opportunities." Sixty workers in Germany and 43 more in Princeton are getting pink slips. The remaining staff of 114 will be about evenly split between Germany and Princeton after GPC's Waltham, MA facility is closed.

"Our goal of having approximately two years of operating cash on hand at the end of 2007 has sadly necessitated very significant staff reductions on both sides of the Atlantic," says CEO Bernd R. Seizinger.

- see this release
- read the AFX report for more

Related Articles:
GPC Biotech reports Q3 results, layoffs. Report
GPC shares crater on Phase III cancer failure. Report
FDA delay forces cutbacks at GPC Biotech. Report
GPC yanks FDA application for satraplatin. Report
FDA questions satraplatin. Report
Top 5 layoffs of 2007. Report

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.